$1,318.00
This Market Spotlight report covers the Eating Disorders market, comprising key marketed and pipeline drugs, clinical trials, probability of success, and a 10-year disease prevalence forecast, and as well as presenting drug-specific revenue forecasts.
This Market Spotlight report covers the Eating Disorders market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, probability of success, a 10-year disease prevalence forecast, and as well as presenting drug-specific revenue forecasts.
Key Takeaways
CONTENTS
5 OVERVIEW
6 KEY TAKEAWAYS
7 DISEASE BACKGROUND
7 Subtypes
8 TREATMENT
8 Psychotherapy
8 Medications
9 EPIDEMIOLOGY
18 MARKETED DRUGS
20 PIPELINE DRUGS
24 KEY UPCOMING EVENTS
25 PROBABILITY OF SUCCESS
26 REVENUE OPPORTUNITY
27 CLINICAL TRIAL LANDSCAPE
28 Sponsors by status
29 Sponsors by phase
31 BIBLIOGRAPHY
33 APPENDIX
LIST OF FIGURES
11 Figure 1: Trends in worldwide prevalent cases of eating disorders in females aged 10–19 years, 2021–30
20 Figure 2: Overview of pipeline drugs for eating disorders in the US
20 Figure 3: Pipeline drugs for eating disorders, by company
21 Figure 4: Pipeline drugs for eating disorders, by drug type
21 Figure 5: Pipeline drugs for eating disorders, by classification
24 Figure 6: Key upcoming events in eating disorders
25 Figure 7: Probability of success in the eating disorders pipeline
27 Figure 8: Clinical trials in eating disorders
27 Figure 9: Top 10 drugs for clinical trials in eating disorders
28 Figure 10: Top 10 companies for clinical trials in eating disorders
28 Figure 11: Trial locations in eating disorders
29 Figure 12: Eating disorders trials status
30 Figure 13: Eating disorders trials sponsors, by phase
LIST OF TABLES
10 Table 1: Worldwide prevalent cases of eating disorders in females aged 10–19 years, 2021–30
12 Table 2: Prevalent cases of eating disorders in females aged 10–19 years in Africa, 2021–30
13 Table 3: Prevalent cases of eating disorders in females aged 10–19 years in Asia, 2021–30
14 Table 4: Prevalent cases of eating disorders in females aged 10–19 Years in Oceania, 2021–30
15 Table 5: Prevalent cases of eating disorders in children aged 10–19 years in Latin America and the Caribbean, 2021–30
16 Table 6: Prevalent cases of eating disorders in children aged 10–19 years in Northern America, 2021–30
17 Table 7: Prevalent cases of eating disorders in all ages in Europe, 2021–30
19 Table 8: Marketed drugs for eating disorders
22 Table 9: Pipeline drugs for eating disorders in the US
26 Table 10: Historical global sales, by drug ($m), 2017–21
26 Table 11: Forecasted global sales, by drug ($m), 2022–26
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!